Tumor-receptor imaging in breast cancer: A tool for patient selection and response monitoring

Current Molecular Medicine

Volumn 13, Issue 10, 2013, Pages 1506-1522

  Heskamp, S ^a   van Laarhoven, H W M ^a,b   Oyen, W J G ^a   van der Graaf, W T A ^a   Boerman, O C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Breast cancer; Molecular imaging; Patient selection; Pet; Response monitoring; Spect

Indexed keywords

4 (3 BROMOANILINO) 6, 7 DIMETHOXYQUINAZOLINE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANASTROZOLE; ANTHRACYCLINE; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ESTROGEN RECEPTOR; FIBRONECTIN RECEPTOR; FULVESTRANT; GEFITINIB; LAPATINIB; LETROZOLE; N (3 CHLOROPHENYL) 3 [3, 5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2, 3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROGESTERONE RECEPTOR; SOMATOMEDIN C RECEPTOR; SORAFENIB; TAMOXIFEN; TRACER; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR 1; VITRONECTIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; BONE SCINTISCANNING; BREAST CANCER; CANCER PROGNOSIS; CANCER SCREENING; CARDIOTOXICITY; CELL MIGRATION; CELL PROLIFERATION; GATED SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS (TOPIC); MOLECULAR IMAGING; NONHUMAN; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; REVIEW; TUMOR GROWTH; TUMOR INVASION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DIAGNOSTIC IMAGING; DRUG MONITORING; FEMALE; HUMANS; PATIENT SELECTION; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84889076059     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524013666131111120638     Document Type: Review

References (166)

1. Effects of chemotherapy and hormonal therapy for earlybreast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
2. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breastcancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-34.
3. Tolmachev V, Malmberg J, Hofstrom C, et al. Imaging ofInsulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule 111In-DOTA-ZIGF1R:4551. J Nucl Med 2012; 53: 90-7.
4. Lee JH, Rosen EL, Mankoff DA. The role of radiotracerimaging in the diagnosis and management of patients with breast cancer: part 1-overview, detection, and staging. J Nucl Med 2009; 50: 569-81.
5. Lee JH, Rosen EL, Mankoff DA. The role of radiotracerimaging in the diagnosis and management of patients withbreast cancer: part 2-response to therapy, other indications, and future directions. J Nucl Med 2009; 50: 738-48.
6. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitialfluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 2004; 4: 806-13.
7. Jain RK. Transport of molecules, particles, and cells in solidtumors. Annu Rev Biomed Eng 1999; 1: 241-63.
8. zum Buschenfelde CM, Hermann C, Schmidt B, Peschel C, Bernhard H. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res 2002; 62: 2244-7.
9. Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: anoestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 2004; 90 Suppl 1: S2-6.
10. Kramer-Marek G, Gijsen M, Kiesewetter DO, et al. Potentialof PET to Predict the Response to Trastuzumab Treatment in an ErbB2-Positive Human Xenograft Tumor Model. J Nucl Med 2012.
11. Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ. Trastuzumab-induced HER reprogramming in resistant breast carcinoma cells. Cancer Res 2009; 69: 2191-4.
12. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer ResTreat 2002; 76: 27-36.
13. Thomas C, Gustafsson JA. The different roles of ERsubtypes in cancer biology and therapy. Nat Rev Cancer 2011; 11: 597-608.
14. Hammond ME, Hayes DF, Dowsett M, et al. AmericanSociety of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-95.
15. Hoefnagel LD, van de Vijver MJ, van Slooten HJ, et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res 2010; 12: R75.
16. Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J. Loss ofestrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996; 14: 2584-9.
17. Spataro V, Price K, Goldhirsch A, et al. Sequential estrogenreceptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group). Ann Oncol 1992; 3: 733-40.
18. Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med 1984; 25: 1212-21.
19. Dehdashti F, Mortimer JE, Siegel BA, et al. Positrontomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995; 36: 1766-74.
20. Peterson LM, Mankoff DA, Lawton T, et al. Quantitativeimaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 2008; 49: 367-74.
21. Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 1996; 2: 933-9.
22. McGuire AH, Dehdashti F, Siegel BA, et al. Positrontomographic assessment of 16 alpha-[18F] fluoro-17 betaestradiol uptake in metastatic breast carcinoma. J Nucl Med 1991; 32: 1526-31.
23. Linden HM, Stekhova SA, Link JM, et al. Quantitativefluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 2006; 24: 2793-9.
24. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001; 19: 2797-803.
25. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of metabolic flare to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999; 26: 51-6.
26. Dehdashti F, Mortimer JE, Trinkaus K, et al. PET-basedestradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 2009; 113: 509-17.
27. Linden HM, Kurland BF, Peterson LM, et al. Fluoroestradiolpositron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res 2011; 17: 4799-805.
28. van Kruchten M, Glaudemans AW, de Vries EF, et al. PETImaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical Dilemma. J Nucl Med 2012.
29. Rijks LJ, Bakker PJ, van Tienhoven G, et al. Imaging ofestrogen receptors in primary and metastatic breast cancer patients with iodine-123-labeled Z-MIVE. J Clin Oncol 1997; 15: 2536-45.
30. Rijks LJ, Boer GJ, Endert E, de Bruin K, Janssen AG, vanRoyen EA. The Z-isomer of 11 beta-methoxy-17 alpha-[123I]iodovinylestradiol is a promising radioligand for estrogen receptor imaging in human breast cancer. Nucl Med Biol 1997; 24: 65-75.
31. Bennink RJ, Rijks LJ, van Tienhoven G, Noorduyn LA, Janssen AG, Sloof GW. Estrogen receptor status in primary breast cancer: iodine 123-labeled cis-11beta-methoxy-17alpha-iodovinyl estradiol scintigraphy. Radiology 2001; 220: 774-9.
32. Bennink RJ, van Tienhoven G, Rijks LJ, Noorduyn AL, Janssen AG, Sloof GW. In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer. J Nucl Med 2004; 45: 1-7.
33. Kurland BF, Peterson LM, Lee JH, et al. Between-patient andwithin-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. J Nucl Med 2011; 52: 1541-9.
34. Horwitz KB, Koseki Y, McGuire WL. Estrogen control ofprogesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 1978; 103: 1742-51.
35. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002; 76: 27-36.
36. Rakha EA, El-Sayed ME, Green AR, et al. Biologic andclinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007; 25: 4772-8.
37. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003; 21: 1973-9.
38. Verhagen A, Studeny M, Luurtsema G, et al. Metabolism of a [18F]fluorine labeled progestin (21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone) in humans: a clue for future investigations. Nucl Med Biol 1994; 21: 941-52.
39. Dehdashti F, McGuire AH, Van Brocklin HF, et al. Assessment of 21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J Nucl Med 1991; 32: 1532-7.
40. Lee JH, Zhou HB, Dence CS, Carlson KE, Welch MJ, Katzenellenbogen JA. Development of [F-18]fluorine-substituted Tanaproget as a progesterone receptor imaging agent for positron emission tomography. Bioconjug Chem 2010; 21: 1096-104.
41. Zhou D, Carlson KE, Katzenellenbogen JA, Welch MJ. Bromine-and iodine-substituted 16alpha,17alpha-dioxolane progestins for breast tumor imaging and radiotherapy: synthesis and receptor binding affinity. J Med Chem 2006; 49: 4737-44.
42. Dehdashti F, Laforest R, Gao F, et al. Assessment ofProgesterone Receptors in Breast Carcinoma by PET with 21-18F-Fluoro-16alpha,17alpha-[(R)-(1'-alpha-furylmethylidene)Dioxy]-19-Norpregn-4-Ene-3,20-Dione. J Nucl Med 2012; 53: 363-70.
43. Baselga J, Swain SM. Novel anticancer targets: revisitingERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9: 463-75.
44. Meric-Bernstam F, Hung MC. Advances in targeting humanepidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res 2006; 12: 6326-30.
45. Burstein HJ. The distinctive nature of HER2-positive breastcancers. N Engl J Med 2005; 353: 1652-4.
46. Bang YJ, Van CE, Feyereislova A, et al. Trastuzumab incombination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-97.
47. Marty M, Cognetti F, Maraninchi D, et al. Randomized phaseII trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265-74.
48. Slamon DJ, Leyland-Jones B, Shak S, et al. Use ofchemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
49. Geyer CE, Forster J, Lindquist D, et al. Lapatinib pluscapecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-43.
50. Harris L, Fritsche H, Mennel R, et al. American Society ofClinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-312.
51. Tuma RS. Inconsistency of HER2 test raises questions. JNatl Cancer Inst 2007; 99: 1064-5.
52. Wolff AC, Hammond ME, Schwartz JN, et al. AmericanSociety of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-45.
53. Lower EE, Glass E, Blau R, Harman S. HER-2/neuexpression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009; 113: 301-6.
54. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005; 93: 552-6.
55. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006; 24: 2276-82.
56. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010; 87: 586-92.
57. de Korte MA, de Vries EG, Lub-de Hooge MN, et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007; 43: 2046-51.
58. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 2005; 56: 361-9.
59. Behr TM, Behe M, Wormann B. Trastuzumab and breastcancer. N Engl J Med 2001; 345: 995-6.
60. McLarty K, Cornelissen B, Cai Z, et al. Micro-SPECT/CT with111In-DTPA-pertuzumab sensitively detects trastuzumabmediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med 2009; 50: 1340-8.
61. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004; 22: 701-6.
62. Akhurst T, Morris PG, Modi S, et al. Positron emissiontomography (PET) with radiolabeled F(ab')2-trastuzumab fragments in patients (pts) with HER2-positive metastatic breast cancer (MBC): Initial feasibility results. Breast Cancer Symposium 2008.
63. Lofblom J, Feldwisch J, Tolmachev V, Carlsson J, Stahl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010; 584: 2670-80.
64. Nygren PA. Alternative binding proteins: affibody bindingproteins developed from a small three-helix bundle scaffold. FEBS J 2008; 275: 2668-76.
65. Heskamp S, Laverman P, Rosik D, et al. Imaging of HumanEpidermal Growth Factor Receptor Type 2 Expression with 18F-Labeled Affibody Molecule ZHER2:2395 in a Mouse Model for Ovarian Cancer. J Nucl Med 2012; 53: 146-53.
66. Tolmachev V, Wallberg H, Sandstrom M, Hansson M, Wennborg A, Orlova A. Optimal specific radioactivity of antiHER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nucl Med Mol Imaging 2011; 38: 531-9.
67. Baum RP, Prasad V, Muller D, et al. Molecular imaging ofHER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled affibody molecules. J Nucl Med 2010; 51: 892-7.
68. Hynes NE, Lane HA. ERBB receptors and cancer: thecomplexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-54.
69. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemicaland clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-74.
70. Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 1994; 29: 41-9.
71. Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinicalsignificance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992; 13: 3-17.
72. Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001:randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012; 30: 2615-23.
73. Modi S, D'Andrea G, Norton L, et al. A phase I study ofcetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer 2006; 7: 270-7.
74. Goldenberg A, Masui H, Divgi C, Kamrath H, Pentlow K, Mendelsohn J. Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody. J Natl Cancer Inst 1989; 81: 1616-25.
75. Dadparvar S, Krishna L, Miyamoto C, et al. Indium-111-labeled anti-EGFr-425 scintigraphy in the detection of malignant gliomas. Cancer 1994; 73: 884-9.
76. Hebbar M, Wacrenier A, Desauw C, et al. Lack of usefulnessof epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 2006; 17: 855-7.
77. Chung KY, Shia J, Kemeny NE, et al. Cetuximab showsactivity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-10.
78. Aerts HJ, Dubois L, Perk L, et al. Disparity between in vivoEGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 2009; 50: 123-31.
79. Katsios C, Ziogas DE, Roukos DH. Colorectal cancer:cetuximab, KRAS, BRAF, PIK3CA mutations and beyond. Expert Rev Gastroenterol Hepatol 2010; 4: 525-9.
80. Achmad A, Hanaoka H, Yoshioka H, et al. Predictingcetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography. Cancer Sci 2012; 103: 600-5.
81. Mishani E, Hagooly A. Strategies for molecular imaging ofepidermal growth factor receptor tyrosine kinase in cancer. J Nucl Med 2009; 50: 1199-202.
82. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lungcancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
83. Yeh HH, Ogawa K, Balatoni J, et al. Molecular imaging ofactive mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc Natl Acad Sci U S A 2011; 108: 1603-8.
84. Memon AA, Weber B, Winterdahl M, et al. PET imaging ofpatients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer. Br J Cancer 2011; 105: 1850-5.
85. Weber B, Winterdahl M, Memon A, et al. Erlotinibaccumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol 2011; 6: 1287-9.
86. Meng X, Loo BW, Jr., Ma L, Murphy JD, Sun X, Yu J. Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study. J Nucl Med 2011; 52: 1573-9.
87. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27: 4966-72.
88. Miller K, Wang M, Gralow J, et al. Paclitaxel plusbevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-76.
89. D'Agostino RB, Sr. Changing end points in breast-cancerdrug approval-the Avastin story. N Engl J Med 2011; 365: e2.
90. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvantchemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366: 299-309.
91. Castellani P, Viale G, Dorcaratto A, et al. The fibronectinisoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994; 59: 612-8.
92. Pini A, Viti F, Santucci A, et al. Design and use of a phagedisplay library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998; 273: 21769-76.
93. Santimaria M, Moscatelli G, Viale GL, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003; 9: 571-9.
94. Haubner R, Weber WA, Beer AJ, et al. Noninvasivevisualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2005; 2: e70.
95. Bach-Gansmo T, Danielsson R, Saracco A, et al. Integrinreceptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med 2006; 47: 1434-9.
96. Kenny LM, Coombes RC, Oulie I, et al. Phase I trial of thepositron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 2008; 49: 879-86.
97. Ma Q, Ji B, Jia B, et al. Differential diagnosis of solitarypulmonary nodules using mTc-3P-RGD scintigraphy. Eur J Nucl Med Mol Imaging 2011; 38: 2145-52.
98. Kim JH, Lee JS, Kang KW, et al. Whole-Body Distributionand Radiation Dosimetry of (68)Ga-NOTA-RGD, a Positron Emission Tomography Agent for Angiogenesis Imaging. Cancer Biother Radiopharm 2012; 27: 65-71.
99. Beer AJ, Haubner R, Goebel M, et al. Biodistribution andpharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 2005; 46: 1333-41.
100. Beer AJ, Haubner R, Sarbia M, et al. Positron emissiontomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006; 12: 3942-9.
101. Beer AJ, Haubner R, Wolf I, et al. PET-based humandosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med 2006; 47: 763-9.
102. Beer AJ, Grosu AL, Carlsen J, et al. 18F galacto-RGDpositron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007; 13: 6610-6.
103. Beer AJ, Niemeyer M, Carlsen J, et al. Patterns ofalphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med 2008; 49: 255-9.
104. Schnell O, Krebs B, Carlsen J, et al. Imaging of integrinalpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol 2009; 11: 861-70.
105. Felding-Habermann B. Integrin adhesion receptors in tumormetastasis. Clin Exp Metastasis 2003; 20: 203-13.
106. Felding-Habermann B, O'Toole TE, Smith JW, et al. Integrinactivation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A 2001; 98: 1853-8.
107. Gasparini G, Brooks PC, Biganzoli E, et al. Vascular integrinalpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res 1998; 4: 2625-34.
108. Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692. Acta Radiol 2010; 51: 40-6.
109. Cai W, Chen K, Mohamedali KA, et al. PET of vascularendothelial growth factor receptor expression. J Nucl Med 2006; 47: 2048-56.
110. Li S, Peck-Radosavljevic M, Kienast O, et al. Imaginggastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. Ann Oncol 2003; 14: 1274-7.
111. Stollman TH, Scheer MG, Leenders WP, et al. Specificimaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody. Int J Cancer 2008; 122: 2310-4.
112. Nagengast WB, de Vries EG, Hospers GA, et al. In vivoVEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007; 48: 1313-9.
113. Scheer MG, Stollman TH, Boerman OC, et al. Imaging livermetastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression. Eur J Cancer 2008; 44: 1835-40.
114. Desar IM, Stillebroer AB, Oosterwijk E, et al. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib. J Nucl Med 2010; 51: 1707-15.
115. Nagengast WB, Hooge MN, van Straten EM, et al. VEGF-SPECT with 111In-bevacizumab in stage III/IV melanoma patients. Eur J Cancer 2011; 47: 1595-602.
116. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGFsystem in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28: 20-47.
117. Yerushalmi R, Gelmon KA, Leung S, et al. Insulin-like growthfactor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat 2011.
118. Railo MJ, von SK, Pekonen F. The prognostic value ofinsulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer 1994; 30A: 307-11.
119. Dallas NA, Xia L, Fan F, et al. Chemoresistant colorectalcancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009; 69: 1951-7.
120. Eckstein N, Servan K, Hildebrandt B, et al. Hyperactivation ofthe insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 2009; 69: 2996-3003.
121. Molloy CA, May FE, Westley BR. Insulin receptor substrate-1expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J Biol Chem 2000; 275: 12565-71.
122. Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 2007; 13: 2795-803.
123. Gualberto A, Pollak M. Emerging role of insulin-like growthfactor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009; 28: 3009-21.
124. Cao L, Yu Y, Darko I, et al. Addiction to elevated insulin-likegrowth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008; 68: 8039-48.
125. Zha J, O'Brien C, Savage H, et al. Molecular predictors ofresponse to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther 2009; 8: 2110-21.
126. Cornelissen B, McLarty K, Kersemans V, Reilly RM. Thelevel of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin). Nucl Med Biol 2008; 35: 645-53.
127. Sun BF, Kobayashi H, Le N, et al. Biodistribution of 125I-labeled des(1-3) insulin-like growth factor I in tumor-bearing nude mice and its in vitro catabolism. Cancer Res 1997; 57: 2754-9.
128. Sun BF, Kobayashi H, Le N, et al. Effects of insulinlikegrowth factor binding proteins on insulinlike growth factor-I biodistribution in tumor-bearing nude mice. J Nucl Med 2000; 41: 318-26.
129. Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, et al. ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med 2010; 51: 1565-72.
130. Fleuren ED, Versleijen-Jonkers YM, van de Luijtgaarden AC, et al. Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507. Clin Cancer Res 2011.
131. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009; 15: 2207-14.
132. Camp RL, Rimm EB, Rimm DL. Met expression is associatedwith poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999; 86: 2259-65.
133. Ghoussoub RA, Dillon DA, D'Aquila T, Rimm EB, Fearon ER, Rimm DL. Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 1998; 82: 1513-20.
134. Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res 2005; 11: 2222-8.
135. Shattuck DL, Miller JK, Carraway KL, 3rd, Sweeney C. Metreceptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 2008; 68: 1471-7.
136. Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, Weiser MR. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res 2011; 17: 472-82.
137. Hay RV, Cao B, Skinner RS, et al. Radioimmunoscintigraphyof human met-expressing tumor xenografts using met3, a new monoclonal antibody. Clin Cancer Res 2003; 9: 3839S-44S.
138. Perk LR, Stigter-van Walsum M, Visser GW, et al. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging 2008; 35: 1857-67.
139. Wu C, Tang Z, Fan W, et al. In vivo positron emissiontomography (PET) imaging of mesenchymal-epithelial transition (MET) receptor. J Med Chem 2010; 53: 139-46.
140. Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP. The upgraded role of HER3 and HER4 receptors in breast cancer. Crit Rev Oncol Hematol 2010; 74: 73-8.
141. Schoeberl B, Faber AC, Li D, et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010; 70: 2485-94.
142. van der Horst EH, Murgia M, Treder M, Ullrich A. Anti-HER-3MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies. Int J Cancer 2005; 115: 519-27.
143. Hickinson DM, Klinowska T, Speake G, et al. AZD8931, anequipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res 2010; 16: 1159-69.
144. Dewji MR. Early phase I data on an irreversible pan-erbinhibitor: CI-1033. What did we learn? J Chemother 2004; 16 Suppl 4: 44-8.
145. Feng SM, Sartor CI, Hunter D, et al. The HER4 cytoplasmicdomain, but not its C terminus, inhibits mammary cell proliferation. Mol Endocrinol 2007; 21: 1861-76.
146. Sassen A, Rochon J, Wild P, et al. Cytogenetic analysis ofHER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 2008; 10: R2.
147. Yonemori K, Tsuta K, Shimizu C, et al. Immunohistochemicalexpression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. J Surg Oncol 2010; 101: 222-7.
148. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003; 200: 290-7.
149. Sassen A, Diermeier-Daucher S, Sieben M, et al. Presenceof HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer. Breast Cancer Res 2009; 11: R50.
150. Stickeler E, Pils D, Klar M, et al. Basal-like molecular subtypeand HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer. Oncol Rep 2011; 26: 1037-45.
151. Kronqvist N, Malm M, Gostring L, et al. Combining phageand staphylococcal surface display for generation of ErbB3-specific Affibody molecules. Protein Eng Des Sel 2011; 24: 385-96.
152. Courjal F, Cuny M, Simony-Lafontaine J, et al. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res 1997; 57: 4360-7.
153. Turner N, Lambros MB, Horlings HM, et al. Integrativemolecular profiling of triple negative breast cancers identifiesamplicon drivers and potential therapeutic targets. Oncogene 2010; 29: 2013-23.
154. Sharpe R, Pearson A, Herrera-Abreu MT, et al. FGFRSignaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo. Clin Cancer Res 2011; 17: 5275-86.
155. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalkbetween tumor cells and their microenvironment. Blood 2006; 107: 1761-7.
156. Cabioglu N, Sahin AA, Morandi P, et al. Chemokinereceptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol 2009; 20: 1013-9.
157. Salvucci O, Bouchard A, Baccarelli A, et al. The role ofCXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 2006; 97: 275-83.
158. Li YM, Pan Y, Wei Y, et al. Upregulation of CXCR4 isessential for HER2-mediated tumor metastasis. Cancer Cell 2004; 6: 459-69.
159. Oda Y, Yamamoto H, Tamiya S, et al. CXCR4 and VEGFexpression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol 2006; 19: 738-45.
160. Cabioglu N, Summy J, Miller C, et al. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 2005; 65: 6493-7.
161. Porcile C, Bajetto A, Barbieri F, et al. Stromal cell-derivedfactor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp Cell Res 2005; 308: 241-53.
162. Rhodes LV, Short SP, Neel NF, et al. Cytokine receptorCXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res 2011; 71: 603-13.
163. Liang Z, Wu T, Lou H, et al. Inhibition of breast cancermetastasis by selective synthetic polypeptide against CXCR4. Cancer Res 2004; 64: 4302-8.
164. Woodard LE, Nimmagadda S. CXCR4-based imagingagents. J Nucl Med 2011; 52: 1665-9.
165. Nimmagadda S, Pullambhatla M, Stone K, Green G, Bhujwalla ZM, Pomper MG. Molecular imaging of CXCR4receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res 2010; 70: 3935-44.
166. Wong JY, Raubitschek A, Yamauchi D, et al. A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. Cancer Biother Radiopharm 2010; 25: 387-94.